Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2026 | Outperform → Perform | Oppenheimer | |
| 3/4/2026 | $14.00 | Buy → Neutral | B. Riley Securities |
| 12/3/2025 | $27.00 | Outperform | Oppenheimer |
| 9/12/2025 | $28.00 | Buy | B. Riley Securities |
| 8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
| 4/12/2024 | $21.00 | Buy | BTIG Research |
| 1/8/2024 | Outperform → In-line | Evercore ISI | |
| 5/23/2022 | $12.00 | Outperform | SVB Leerink |
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
SCHEDULE 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
Oppenheimer downgraded Theravance Biopharma from Outperform to Perform
B. Riley Securities downgraded Theravance Biopharma from Buy to Neutral and set a new price target of $14.00
Oppenheimer initiated coverage of Theravance Biopharma with a rating of Outperform and set a new price target of $27.00
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder valueYUPELRI® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 mil
Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO)Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in achieving $100 million 2026 TRELEGY milestone1Strategic Review Committee accelerating ongoing efforts to evaluate alternatives to maximize shareholder valueOrganizational restructuring to reduce cost base by approximately 60% (or approximately $70 million); expected to result in the Company generating approximately $60 - $70 million of annualized cash flowStreamlined portfolio focused on YUPELRI®, a growing produc
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder valueYUPELRI® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 mil
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si